Eli Lilly Stock Surges on Blockbuster GLP-1 Sales and Raised 2026 Outlook

Shares of Eli Lilly and Company (LLY) surged in morning trading after the pharmaceutical giant reported second-quarter 2026 results that far surpassed Wall Street estimates and raised its full-year revenue forecast.

The stock climbed 8.6% to $1,212.13, snapping a five-day losing streak and approaching its record high of $1,249.45, as investors rewarded the company's strong execution in the high-growth diabetes and obesity drug market.

Stellar Earnings and Upgraded Outlook

Eli Lilly announced a significant beat on both its top and bottom lines for the second quarter. The strong performance prompted the company to lift its financial projections for the full year.

Key figures from the report include:

• Adjusted Earnings Per Share: $8.38, well above the consensus estimate of $6.01.
• Revenue: $22.97 billion, exceeding the expected $20.73 billion.
• Full-Year 2026 Revenue Guidance: Raised to a range of $85 billion to $87 billion, up from a prior forecast of $82 billion to $85 billion.

GLP-1 Therapies Fuel Growth

Ad

The quarter's exceptional results were overwhelmingly driven by the company's flagship GLP-1 therapies. Sales for Mounjaro, its type 2 diabetes treatment, grew 91% to $9.94 billion, while its weight-loss drug Zepbound saw sales grow 46% to $4.93 billion.

Together, the two drugs accounted for nearly two-thirds of Lilly's total quarterly revenue. The company also reported strong international performance, with revenue outside the U.S. jumping 80% to $8.6 billion, propelled by a 113% surge in volume. Additionally, Lilly reported its first quarterly revenue for Foundayo, its new oral weight-loss pill, which brought in $98 million.

Market Reaction and Competitive Landscape

Lilly's stock significantly outpaced the broader market, which saw modest gains with the S&P 500 up 0.6% and the Dow Jones Industrial Average adding 0.9%.

The report stood in sharp contrast to that of rival Novo Nordisk, which also raised its 2026 guidance but saw its shares trade lower amid investor concerns over its oral drug sales. This divergence appeared to reinforce investor confidence in Eli Lilly's competitive position and market execution.